Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 4
Submit an article Journal homepage
15
Views
0
CrossRef citations to date
0
Altmetric
Review

Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis

Jennifer M Stephens Abt Associates Clinical Trials, HERQuLES Group, 4800 Montgomery Lane, Suite 600, Bethesda, MD 20814, USA. [email protected]
,
Christopher F Bell Abt Associates, Clinical Trials, HERQuLES Group, 4800 Montgomery Lane, Suite 600, Bethesda, MD 20814, USA.
,
Josephine M Wong Pharmacia Corporation
,
Beatriz M Peña Pfizer Inc, New York, NY, USA. [email protected]
,
Seema Haider Pfizer Inc, Groton, CT, USA. [email protected]
&
Chris L Pashos Abt Associates Clinical Trials, Health Economic Research and Quality of Life Evaluation Services (HERQuLES), Cambridge, MA, USA. [email protected]
Pages 441-455 | Published online: 09 Jan 2014

References

  • Zazoico G. COX-2 Inhibitors: the battle for market dominance. Drug- Market Devel 12(5), 131–137 (2001).
  • Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 28, 686–692 (1985).
  • de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand. Rheumatol 96 (Suppl.), 49–53 (1992).
  • Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Rheumatol 26(Suppl. 56), 31–36 (1999).
  • Goldenberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Gun. Ther 21, 1837–1852 (1999).
  • Fung FIB, Kirschenbaum HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Gun. Ther 21, 1131–1157 (1999).
  • Goldstein JL, Correa P, Zhao WW et al Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared with naproxen in patients with arthritis. Am. Gastroenterol 96,1019–1027 (2001).
  • Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl. I Med. 340,1888–1899 (1999).
  • Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. I Med. 105, S31—S38 (1998).
  • Langman MJ, Weil J, Wainwright P et al Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 343, 1075–1078 (1994).
  • Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. 115, 787–796 (1991).
  • McKenna F, Borenstein D, Wendt H et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scantl Rheumatol 30,11–18 (2001).
  • Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. Rheumatol 26\(Suppl. 56), 18–24 (1999).
  • Seibert K, Masferrer JL, Fu JY et al. The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv. Prostaglandin Thmmboxane Leukot. Res. 21A, 45–51 (1991).
  • Lipsky PE. Introduction. The role of COX-2 specific inhibitors in clinical practice. Ainj Mer1110 (Suppl. 3A), S1—S2 (2001).
  • Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2-specific inhibitors. Am. Med110(Suppl. 3A), S6—S12 (2001).
  • Zabinski RA, Burke TA, Johnson J et al An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. PharmacoEconomics 19 (Suppl. 1), 49–58 (2001).
  • Chancellor JV, Hunsche E, de Cruz E, Sarasin FR Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. PharmacoEconomics19\(Suppl. 1), 59–75 (2001).
  • Haglund U, Svarvar P The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology39\(Suppl. 2), 51–56 (2000).
  • Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology 39 (Suppl. 2), 43–50 (2000).
  • Pettitt D, Goldstein JL, McGuire A, Schwartz JS, Burke T, Maniadakis N. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology39\(Suppl. 2), 33–42 (2000).
  • Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti inflammatory drugs for the treatment of osteoarthritis. Gun. Ther 23,1061–1079 (2001).
  • El-Serag FIB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs. The use of a nomogram in cost-effectiveness analysis. Arch. Intern. Med. 162, 2105–2110 (2002).
  • Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arth. Rheum. 49(3), 283–292 (2003).
  • •Good cost-effectiveness study, sponsored by Canadian authorities and followed Canadian guidelines for economic
  • •• evaluation of pharmaceuticals. Found both rofecoxib and celecoxib to be cost-effective in the elderly.
  • Marshall JK, Pellissier JM, Afford CL, Kong S, X, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. PharmacoEconomics 19, 1039–1049 (2001).
  • •Cost-effectiveness study from a Canadian payer perspective.
  • NICE Appraisal Team. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COX-II inhibitors) for rheumatoid arthritis and osteoarthritis. National Institute for Clinical Excellence, UK (2000).
  • Kong, SX, Pellissier, JM. Health economic evaluation of rofecoxib versus conventional NSAIDs in the treatment of osteoarthritis in Switzerland. European Congress of Rheumatology, Annual Meeting of the EUropean League Against Rheumatism (EULAR) SAT0241. (2003).
  • Kamath CC, Kremers HM, Vanness DJ, °Fallon WM, Cabanela RL, Gabriel SE The cost-effectiveness of acetaminophen, NSAIDs and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value 1-kalth. 6(2), 144–57 (2001).
  • •• Comprehensive cost-effectiveness study comparing acetaminophen, ibuprofen, ibuprofen plus misoprostol, celecoxib and rofecoxib. Found acetaminophen drug of choice for average gastrointestinal (GI) risk patients.
  • Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2 specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am. J. Manage. Ca,r8, S392—S400 (2002).
  • Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2 specific inhibitors. Am. J. Manage. Cwe 8, S401—S413 (2002).
  • Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2 specific inhibitors. Am. J. Manage. Care 8, S414—S427 (2002).
  • Lame L. Nonsteroidal anti-inflammatory drug gastropathy. Castrointest. Enclosc. Gun. N. Am. 6,489–504 (1996).
  • Silverstein FE, Graham DY, Senior JR et al Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Merl 123,241–249 (1995).
  • Silverstein FE, Faich G, Goldstein JL et al Gastrointestinal toxicity with celecoxib versus nonsteroidal anti inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAIVIA 284, 1247–1255 (2000).
  • •• Landmark study on the 6-month GI toxicity of celecoxib.
  • Bombardier C, Lame L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. J. Merl 343, 1520–1528 (2000).
  • ••Landmark study on the GI toxicityof rofecoxib.
  • Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch. Intern. Med. 160,2093-2099 (2000).
  • Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 343, 769–772 (1994).
  • Lanas A. Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. Ital. J. Castmenterol Hepatol 31 (Suppl. 1), S37—S42 (1999).
  • Manek NJ, Lane NE. Osteoarthritis: current concepts in diagnosis and management. Am. Fain. Physician 61, 1795–1804 (2000).
  • Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am. J. Merl 104, S43—S51 (1998).
  • Pharmaceutical Research and Manufacturers of America. New medicines in development for older americans (2002).
  • Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Ther 23,213–227 (2001).
  • Ehrich EW, Schnitzer TJ, McIlwain H et al Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double-blind, placebo-controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J. Rheumatol 26,2438–2447 (1999).
  • Gottesdiener K, Schnitzer T, Fisher C et al Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology41 (9), 1052–1061 (2002).
  • Fiechtner JJ, Sikes, D, Recker, D. A double- blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee. European Congress of Rheumatology, Annual Meeting of the European League Against Rheumatism (EULAR) OP0048. (2001).
  • Makarowski W, Zhao WW Bevirt T, Recker DR Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage10, 290–296 (2002).
  • Kivitz AJ, Eisen G, Zhao WW Recker DP, Verburg KM. The COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. Pan American Congress of Rheumatology, Annual Meeting of the Pan American League Against Rheumatism (PANLAR). (2002).
  • Sikes DH, Agrawal NM, Zhao WW Kent JD, Recker DP, Verburg KM. Incidence of astroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur I Castroenterol Hepatol 14,1101–1111 (2002).
  • Kivitz A, Eisen G, Zhao WW Bevirt T, Recker DR Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. I Fam. Pract. 51,530–537 (2002).
  • Acevedo E, Castaneda O, Ugaz M et al Tolerability profiles of rofecoxib (Vioxx) and arthrotec. A comparison of 6 weeks treatment in patients with osteoarthritis. Scancl I Rheumatol 30,19–24 (2001).
  • Cannon GW, Caldwell JR, Holt P et al Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. 43, 978–987 (2000).
  • Saag K, van der HD, Fisher C et al Rofecoxib, a new cyclooxygenase-2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch. Fain. Med. 9,1124-1134 (2000).
  • Day R, Morrison B, Luza A et a/. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch. Intern Med. 160,1781-1787 (2000).
  • Truitt KE, Sperling RS, Ettinger WH et al A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging 13,112–121 (2001).
  • Bensen WG, Zhao SZ, Burke TA et al Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared with naproxen and placebo. J. Rheumatol. 27,1876-1883 (2000).
  • Lanza FL, Rack ME, Simon TJ et al Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther 13, 761–767 (1999).
  • Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAIVIA 282,1921–1928 (1999).
  • Hawkey C, Lame L, Simon T et al Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 43,370-377 (2000).
  • Lame L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117,776–783 (1999).
  • Lisse JR, Perlman M, Johansson G et al Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. Ann. Intern. Med. 139,539–546 (2003).
  • Schnitzer TJ. Is concern about cardiovascular events with the new coxib class of drugs justified? Medscape Womens Health 6,8 (2001).
  • Goldstein JL, Agrawal NM, Eisen G, Stenson WF et al Significantly improved upper gastrointestinal (UGI) tolerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I Trial. European Congress of Rheumatology, Annual Meeting of the EUropean League Against Rheumatism (EULAR) THU183. (2001).
  • Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern Med 160,2998–3003 (2000).
  • Palmer BE Renal complications associated with use of nonsteroidal anti-inflammatory agents. J. Investig Med 43,516–533 (1995).
  • Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Ann. Rev Pharmacol. Toxicol. 33,435–465 (1993).
  • Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin. Ther 23,1478–1491 (2001).
  • Tive L. Celecoxib clinical profile. Rheumatology39\(Suppl. 2), 21–28 (2000).
  • Bextrae (valdecoxib) product labeling. Pfizer Inc, NY, USA (2004).
  • Boers M. NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet357, 1222–1223 (2001).
  • Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAIVIA 286, 954–959 (2001).
  • Rahme E, Marentette MA, Kong SX, LelorierJ. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 47(6), 595–602 (2002).
  • Mukherjee D, Nissen SE, Topol EJ. Lack of cardioprotective effect of naproxen. Arch. Intern Med. 162(22), 2637 (2002).
  • Fowles RE. Potential cardiovascular effects of COX-2 selective nonsteroidal anti-inflammatory drugs. J. Pain Pall Care Pharm. 17(2), 27–50 (2003).
  • White WB, Faich G, Whelton A et al Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. 89, 425–430 (2002).
  • Ott E, Nussmeier NA, Duke PC et al Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thor. Cardiovas Surg. 125(6), 1481–1492 (2003).
  • March L, Lapsley H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract. Res. Clin. Rheumatol. 15,171–185 (2001).
  • Levy E, Ferme A, Perocheau D, Bono I. Socioeconomic costs of osteoarthritis in France. Rev .Rhum. Ed. Fr 60,63–67 (1993).
  • Bloom BS. The financial effects of arthritis: current and future implications. New Advances in the Treatment of Arthritis and Chronic Pain: Clinical, Economic, and Patient Implications for Managed Care. Proceedings of a preconference symposium held in conjunction with the I I th Annual Meeting of the Academy of Managed Cam Pharmacy 5 (3), 4–6 (1999) .
  • MacLean CH, Knight K, Paulus H, Brook RII, Shekelle PG. Costs attributable toosteoarthritis. j Rheumatol. 25,2213–2218 (1998).
  • Lanes SF, Lanza LL, Radensky PW et al Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 40, 1475–1481 (1997).
  • Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol. 24, 43–48 (1997).
  • Chevat C, Pena BM, Al MJ, Rutten FF. Healthcare resource utilisation and costs of treating NSMD-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics19(Suppl 1), 17–32 (2001).
  • Traynor V, Britt H, Neary S, Sayer GP, Charles J, Meza RA. The management of osteoarthritis in general practice. Results from the Australian Morbidity and Treatment Survey, 1990–1991. Aust. Fam. Physician 23,1971-1978 (1994).
  • Hunsche E, Chancellor JV, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. PhatmacoEconornics 19\(Suppl. 1), 1–15 (2001).
  • de Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. BE J. Rheumatol 34\(Suppl. 1), 19–24 (1995).
  • Knill-Jones RR The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scantl j Rheumatol 96(Suppl.), 59–62 (1992).
  • von Scheele B, Pena B, Wong J, Niculescu L. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. Rheumatology 42 (Suppl. 3), 53–59 (2003).
  • Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scant/. I Rheumatol 33,1–6 (2004).
  • Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists and other antihypertensive drugs. Arch. Intern Med. 158,33–39 (1998).
  • Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 8,18–24 (1997).
  • McIntosh JH, Fung CS, Berry G, Piper DW. Smoking, nonsteroidal anti-inflammatory drugs and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns. Am. J. Epidemiol 128, 761–770 (1988).
  • Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med. 153,1665–1670 (1993).
  • Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann. Intern Med. 114, 735–740 (1991).
  • Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Aim jMi 91,213–222 (1991).
  • Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern Med. 114,257–263 (1991).
  • Bensen WG, Fiechtner JJ, McMillen JI et al Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc. 74,1095-1105 (1999).
  • Goldstein JL, Silverstein FE, Agrawal NM et al Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J. Castroenteml 95, 1681–1690 (2000).
  • Wolfe E Celecoxib substantially reduces GI ulceration compared with nonselective NSAIDs during usual clinical care despite greater risk factors and confounding by indication: experience in 8040 patients. American College of Rheumatology, October 29 — November 2, (2000).
  • Langman MJ, Jensen DM, Watson DJ, et al Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282,1929–1933 (1999).

Websites

  • COX-2 inhibitors or traditional NSAIDs? IMS. 2001 www.ims global.com/insight/news_story/ 0103/news_story_010306.htm. (Accessed July 2004)
  • www.drugstore.com (Accessed July 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.